Lipoprotein(a) and coronary heart disease risk

Current Cardiology Reports

Volumn 1, Issue 2, 1999, Pages 105-111

  Marcovina, Santica M ^a   Hegele, Robert A ^b   Koschinsky, Marlys L ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; PHYSIOLOGY; REVIEW; RISK FACTOR;

CORONARY ARTERIOSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; LIPOPROTEIN(A); RISK FACTORS;

EID: 0033156194     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0067-z     Document Type: Article

References (49)

1. Berg K: A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 1963, 59:362-382.
2. Koschinsky ML, Marcovina SM: Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res 1997, 27:14-23.
3. Albers JJ, Kennedy H, Marcovina SM: Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: evaluation of amino acid analysis data. J Lipid Res 1996, 37:192-196.
4. Brunner C, Kraft H-G, Utermann G, et al.: Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A 1993, 90:11643-11647.
5. Koschinsky ML, Côté GP, Gabel B, et al.: Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993, 268:19819-19825.
6. Callow MJ, Rubin EM: Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo. J Biol Chem 1995, 270:23914-23917.
7. Gabel BR, McLeod RS, Yao Z, et al.: Sequences within the amino terminus of apoB100 mediate its noncovalent association with apo(a). Arterioscler Thromb Vasc Biol 1998, 18:1738-1744.
8. Xu S: Apolipoprotein(a) binds to low-density lipoprotein at two distant sites in lipoprotein(a). Biochemistry 1998, 37:9284-9294.
9. McLean JW, Tomlinson JE, Kuang WJ, et al.: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
10. Lackner C, Cohen JC, Hobbs HH: Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993, 2:933-940.
11. van der Hoek YY, Wittekoek ME, Beisiegel U, et al: The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms. Hum Mol Genet 1993, 2:361-366.
12. Mooser V, Marcovina SM, White AL, et al: Kringle containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into urine. J Clin Invest 1996, 98:2414-2424.
13. Mooser V, Seabra MC, Abedin M, et al: Apolipoprotein(a) kringle 4 containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996, 97:858-864.
14. Edelstein C, Italia JA, Kelzovitch O, et al: Functional and metabolic differences between elastase generated fragments of human lipoprotein(a) at multiple interkringle sites via the enzyme elastase. J Lipid Res 1996, 37:1786-1801.
15. Edelstein C, Italia JA, Scanu AM: Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein (a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. J Biol Chem 1997, 272:11079-11087.
16. Harpel PC, Zhang X, Migliorini M, et al: A new catabolic pathway for the atherogenic lipoprotein, Lp(a): mononuclear cells and neutrophils degrade Lp(a) into two domains reflecting the proteinase activity of human leukocyte elastase (HLE) and cathepsin G (CG). Thromb Haemost 1997, 78(suppl 1):567.
17. Edelstein C, Italia JA, Kelzovitch ON, et al: Metalloproteinase 2 cleaves lipoprotein(a) and apolipoprotein(a) in the linker region between kringles IV 4 and IV 5. Circulation 1997, 96(suppl):1-111.
18. Scanu AM: Proteolytic modifications of lipoprotein (a): potential relevance to its postulated atherothrombogenic role. J Investig Med 1998, 46:359-363.
19. Rath M, Niendorf A, Reblin T, et al: Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989, 9:579-592.
20. Niendorf A, Rath M, Wolf K, et al: Morphological detection and quantification of lipoprotein(a) deposition in atheroma tous lesions of human aorta and coronary arteries. Virchows Arch 1990, 417:105-111.
21. Reblin T, Meyer N, Labeur C, et al: Extraction of lipoprotein (a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis 1995, 113:179-188.
22. Dangas G, Mehran R, Harpel PC, et al: Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998, 32:2035-2042.
23. Poon M, Zhang X, Dunsky KG, et al: Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997, 96:2514-2519.
24. Kojima S, Harpel PC, Rifkin DB: Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol 1991, 113:1439-1445.
25. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al.: The proliferation of human smooth muscle cells is promoted by lipoprotein(a). Science 1993, 260:1655-1658.
26. Grainger DJ, Kemp PR, Liu AC, et al.: Activation of transforming growth factor beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994, 370:460-462.
27. Sangrar W, Bajzar L, Nesheim ME, et al.:. The antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995, 34:5151-5157.
28. Palabrica TM, Liu AC, Aronovitz MJ, et al.: Antifibrinolytic effect of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995, 1:256-259.
29. Biemond BJ, Friederich PW, Koschinsky ML, et al.: Apolipoprotein(a) attenuates fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997, 96:1612-1615.
30. Etingen OR, Hajjar DP, Hajjar KA, et al.: Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991, 266:2459-2465.
31. Li XN, Grenett HE, Benza RL, et al.: Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 1997, 17:3215-3223.
32. Rand ML, Sangrar W, Hancock MA, et al.: Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide, SFLLRN. Arterioscler Thromb Vasc Biol 1998, 8:1393-1399.
33. Marcovina SM, Koschinsky ML: Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998, 82:57U-66U.
34. Craig WY, Neveux LM, Palomaki GE, et al.: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998, 44:2301-2306.
35. Armstrong VW, Cremer P, Eberle E, et al.: The association between serum Lp(a) concentrations and angiographically-assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986, 62:249-257.
36. Maher VM, Brown BG, Marcovina SM, et al.: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995, 274:1771-1774.
37. Hopkins PN, Wu LL, Hunt SC, et al.: Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997, 17:2783-2792.
38. Solymoss BC, Marcil M, Wesolowska E, et al.: Relation of coronary artery disease in women 60 years of age to the combined elevation of serum lipoprotein(a) and total cholesterol to HDL cholesterol ratio. Am J Cardiol 1993, 72:1215-1219.
39. Stubbs P, Seed M, Lane D, et al.: Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998, 19:1355-1364.
40. Weiss SR, Bachorik PS, Becker LC, et al.: Lipoprotein(a) and coronary heart disease risk factors in a racially mixed population: the Johns Hopkins sibling study. Ethn Dis 1998, 8:60-72.
41. Brown SA, Hutchinson R, Morrisett J, et al.: Plasma lipid, lipoprotein cholesterol and apolipoprotein distributions in selected US communities: the atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb Vasc Biol 1993, 13:1139-1158.
42. Jenner JL, Ordovas JM, Lamon-Fava S, et al.: Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 1993, 87:1135-1141.
43. Dahlen GH, Srinivasan SR, Stenlund H, et al.: The importance of serum lipoprotein(a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States. J Intern Med 1998, 244:417-424.
44. Moliterno DJ, Jokinen EV, Miserez AR, et al.: No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995, 15:850-855.
45. Dahlen GH, Weinehall L, Stenlund H, et al.: Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein-A1 protects against primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med 1998, 244:425-430.
46. Cantin B, Gagnon F, Moorjani S, et al.: Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998, 31:519-525.
47. Marcovina SM, Albers JJ, Gabel B, et al.: Effect of the number of apo(a) kringle 4 domains on the immunochemical measurements of Lp(a). Clin Chem 1995, 41: 246-255.
48. Enas EA, Mehta JL: Lipoprotein(a): an important risk factor in coronary artery disease [letter]. J Am Coll Cardiol 1998, 32:1132-1133.
49. Cantin B. Lipoprotein(a): an important risk factor in coronary artery disease [reply]. J Am Coll Cardiol 1998, 32:1133-1134.